41 completed, 5 recruiting, 3 unknown, 2 withdrawn. 32 Phase 1, 12 Phase 2, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Vaccinia: new trials by email Literature Review of Vaccinia trials Research Report on Vaccinia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IDOV-Immune for Advanced Solid Tumors IDOV-Immune (oncolytic vaccinia virus) - Colorectal Cancer, Pancreatic Cancer | Phase 1 | Recruiting | ViroMissile, Inc. | 78 | 2025-08-25 | 2026-08-05 |
| Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer Recombinant human IL-21-expressing oncolytic vaccinia virus injection - Advanced Pancreatic Cancer | Phase 2 | Recruiting | Hangzhou Converd Co., Ltd. | 12 | 2025-05-29 | 2026-02-27 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC - Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma | Phase 2 | Recruiting | Genelux Corporation | 142 | 2024-09-26 | 2026-06-04 |
| Evaluation of Patients' Knowledge of Their Vaccination Status and Their Relationship to Vaccination at Melun Hospital vaccination status - Vaccinia | Unknown | Groupe Hospitalier Sud Ile-de-France | 140 | 2024-07-16 | 2025-06-06 | |
| Evaluating the Human Immune Response to the JYNNEOS Vaccine JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) suspension for subcutaneous injection, Phlebotomy, Research bronchoscopy - Vaccinia, Virus Diseases | Early Phase 1 | Active not recruiting | Washington University School of Medicine | 20 | 2024-06-10 | 2026-10-21 |
| Evaluation of Healthcare Workers Knowledge Regarding Their Vaccination Status at Melun Hospital Vaccinia | Completed | Groupe Hospitalier Sud Ile-de-France | 100 | 2024-02-28 | 2024-10-21 | |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Recruiting | Genelux Corporation | 186 | 2022-08-31 | 2026-08-26 |
| Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact Double Recombinant Vaccinia Virus VV-GMCSF-Lact - Oncolytic Virotherapy | Phase 1 | Completed | "Oncostar" LLC | 34 | 2022-05-11 | 2026-04-21 |
| Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service Coronavirus Disease 2019, Vaccinia | Unknown | Saglik Bilimleri Universitesi | 45 | 2022-05-05 | 2022-05-06 | |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors ASP9801, Pembrolizumab - Metastatic Cancer, Solid Tumors | Phase 1 | Completed | Astellas Pharma Global Development, Inc. | 72 | 2019-09-03 | 2025-04-22 |
| The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years Gardasil - Cancer of Cervix, Vaccinia | Unknown | University of Fukui | 2800 | 2019-08-01 | 2019-07-19 | |
| JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo JYNNEOS (Liquid Formulation), JYNNEOS (Lyophilized Formulation) - Monkeypox Virus Infection | Phase 3 | Completed | Centers for Disease Control and Prevention | 1600 | 2017-02-23 | 2026-04-23 |
| Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer Olvi-Vec, Platinum-doublet with or without bevacizumab - Ovarian Cancer, Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Genelux Corporation | 46 | 2016-05-01 | 2026-06-12 |
| Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Pexastimogene Devacirepvec (Pexa Vec), Sorafenib - Hepatocellular Carcinoma (HCC) | Phase 3 | Completed | SillaJen, Inc. | 459 | 2015-10-01 | 2026-06-08 |
| Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin JX-594 - Ovarian Cancer | Phase 2 | Withdrawn | Andrea McCart | 2014-01-01 | 2014-09-17 | |
| Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer GL-ONC1 - Cancer of Head and Neck | Phase 1 | Completed | Genelux Corporation | 19 | 2012-04-01 | 2015-08-25 |
| A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis GL-ONC1 - Peritoneal Carcinomatosis | Phase 1 / Phase 2 | Completed | Genelux GmbH | 9 | 2012-02-01 | 2025-04-30 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma JX-594, Irinotecan - Colorectal Carcinoma, CRC | Phase 1 / Phase 2 | Completed | Jennerex Biotherapeutics | 52 | 2012-01-01 | 2026-08-05 |
Showing 20 of 53. Sign in to see all of them.
HIV Infections (15) · Neoplasms (8) · Smallpox (7) · Carcinoma, Hepatocellular (5) · Liver Neoplasms (5) · Melanoma (5) · Colorectal Neoplasms (4) · Ovarian Neoplasms (4) · Acquired Immunodeficiency Syndrome (3) · Breast Neoplasms (3) · Carcinoma (3) · Neoplasm Metastasis (3) · Virus Diseases (3) · Carcinoma, Non-Small-Cell Lung (2)
DNA Virus Infections (53) · Infections (53) · Poxviridae Infections (52) · Virus Diseases (50) · Urogenital Diseases (22) · Neoplasms by Site (21) · Genital Diseases (20) · Immune System Diseases (17) · Neoplasms (16) · RNA Virus Infections (16) · Blood-Borne Infections (15) · Communicable Diseases (15) · Immunologic Deficiency Syndromes (15) · Lentivirus Infections (15) · Retroviridae Infections (15)
VaxSyn HIV-1 (gp160) vaccine (8) · HIVAC-1e (6) · Smallpox Vaccine (4) · 130-nm albumin-bound paclitaxel (2) · ACAM2000 (2) · Bevacizumab (2) · Cisplatin (2) · Docetaxel (2) · Hepatitis B Vaccines (2) · Sorafenib (2) · pembrolizumab (2) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (2) · Biosimilar Pharmaceuticals (1) · DryVax vaccine (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
National Institute of Allergy and Infectious Diseases (NIAID) (16) · Jennerex Biotherapeutics (7) · Emergent BioSolutions (4) · Genelux Corporation (4) · Genelux GmbH (2) · Groupe Hospitalier Sud Ile-de-France (2) · "Oncostar" LLC (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Andrea McCart (1) · Astellas Pharma Global Development, Inc. (1) · Bristol-Myers Squibb (1) · Centers for Disease Control and Prevention (1) · David Bartlett (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Hangzhou Converd Co., Ltd. (1)
United States (38) · France (6) · Canada (5) · South Korea (5) · Germany (3) · Australia (2) · China (2) · Hong Kong (2) · Taiwan (2) · United Kingdom (2) · Belgium (1) · Democratic Republic of the Congo (1) · Israel (1) · Italy (1) · New Zealand (1)
Belshe R (5) · Clements ML (3) · Couch R (3) · Dolin R (3) · Levine M (3) · Wright P (3) · Corey L (2) · David Kirn, MD (2) · James Burke, MD (2) · Koff W (2) · Daniel Oertli, M.D. (1) · David H Kirn, MD (1)
PMID 37227734, PMID 11874634, PMID 14577912, PMID 18495536, PMID 19935776, PMID 20466416, PMID 22113474, PMID 23393196, PMID 27851688, PMID 29773661, PMID 30445121, PMID 31413923, PMID 32967791, PMID 33143690, PMID 34454787, PMID 34686353, PMID 36263798, PMID 37666539, PMID 41819114, PMID 41819117, PMID 42383154